- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
- Aurinia to Participate in Upcoming Investor Healthcare Conferences
More ▼
Key statistics
On Monday, Aurinia Pharmaceuticals Inc (IKAP:STU) closed at 4.71, 5.90% above its 52-week low of 4.44, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.70 |
---|---|
High | 4.71 |
Low | 4.70 |
Bid | 4.76 |
Offer | 4.81 |
Previous close | 4.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 143.02m |
Free float | 132.25m |
P/E (TTM) | -- |
Market cap | 737.98m USD |
EPS (TTM) | -0.4363 USD |
Data delayed at least 15 minutes, as of May 06 2024.
More ▼